Clinical Trial Update: Β3-adrenoreceptor As Prognostic Marker in Neuroblastoma and Ewing Sarcoma [NA]

View source ↗

Summary

This completed clinical trial evaluates Beta-3 adrenergic receptor as a prognostic biomarker in neuroblastoma and Ewing sarcoma.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Ewing Sarcoma
• Neuroblastoma

Snippet

Sponsor: Meyer Children's Hospital IRCCS | Conditions: Neuroblastoma, Ewing Sarcoma | NA | Status: COMPLETED